TGFB1 and neoplasm: Via β-catenin activation, TGF-β impairs T cell mediated immune surveillance and subsides DC recruitment to the tumor site, consequently incurring HCC immune escape and resistance to anti-PD1 treatment (Ruiz de Galarreta et al., 2019).